Research

The PAAG Regimen: A Chinese Innovation Redefining First-Line Treatment for Advanced Pancreatic Cancer

May 18, 2026

Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal malignancies worldwide, with a five-year survival rate below 13%. The disease is characterized by a highly immunosuppressive tumor microenvironment, dense desmoplastic stroma, and intrinsic resistance to most systemic therapies. For decades, the standard first-line treatment for metastatic pancreatic cancer has been limited to gemcitabine-based or FOLFIRINOX-based chemotherapy regimens, with only modest improvements in survival outcomes.

Against this backdrop, a landmark randomized controlled trial from China — the RCT-PAAG study (NCT06051851) — has emerged as a compelling signal that rational combination of immunotherapy, antiangiogenic therapy, and chemotherapy may finally begin to crack the therapeutic resistance of this devastating disease. Presented at the 2026 ASCO Gastrointestinal Cancers Symposium, the PAAG regimen developed by Professor Du Juan’s team at Nanjing Drum Tower Hospital (affiliated with Nanjing University Medical School) represents a significant step forward in the medical oncology treatment of advanced pancreatic cancer.

The PAAG Regimen: Rationale and Composition

PAAG stands for Penpulimab + Anlotinib + nab-paclitaxel (Abraxane) + Gemcitabine. This quadruplet regimen integrates three distinct therapeutic mechanisms:

Component	Mechanism	Role in PAAG
Penpulimab	Anti-PD-1 immune checkpoint inhibitor	Reactivates T-cell–mediated antitumor immunity
Anlotinib	Multi-target antiangiogenic TKI (VEGFR, FGFR, PDGFR, c-Kit)	Normalizes tumor vasculature, improves immune cell infiltration, disrupts tumor blood supply
Nab-paclitaxel	Cytotoxic chemotherapy	Disrupts tumor stroma, releases tumor antigens
Gemcitabine	Nucleoside analog chemotherapy	Direct cytotoxicity, immunogenic cell death

The biological rationale is elegant: pancreatic cancer is notoriously an immunologically “cold” tumor with minimal T-cell infiltration. The PAAG strategy addresses this through a synergistic “iron triangle” approach — anlotinib normalizes the aberrant tumor vasculature to facilitate immune cell trafficking, chemotherapy induces immunogenic cell death to release neoantigens, and penpulimab removes the PD-1/PD-L1 immune brake to unleash cytotoxic T-cell activity. This is not a simple drug stacking exercise, but a mechanistically informed combination designed to convert a cold tumor into a hot one.

Key Clinical Results

The RCT-PAAG study enrolled 155 patients in the intention-to-treat (ITT) population (PAAG arm: 103 patients; standard AG arm: 52 patients). Among patients who completed at least one imaging assessment (PAAG: 94; AG: 49), the results were striking:

Endpoint	PAAG Regimen	Standard AG	Improvement	P-value
Median PFS	7.7 months (95% CI: 6.7–8.7)	4.5 months (95% CI: 3.3–5.8)	+71%	P < 0.001
Median OS	Not reached	Not reached	Data maturing	—
ORR (evaluable)	47.87%	28.57%	+68%	P = 0.026
DCR (evaluable)	92.55%	67.35%	+37%	P < 0.001
Grade ≥3 AEs	41.75%	38.46%	Comparable	P = 0.694
Any-grade AEs	93.20%	94.23%	Comparable	P = 1.000

Data cutoff: October 31, 2025. Notably, there were zero treatment-related deaths in either arm.

Interpretation of Key Findings

Progression-Free Survival: The 71% improvement in median PFS (7.7 vs. 4.5 months) is remarkable in the context of metastatic pancreatic cancer, where incremental gains of even weeks are considered clinically meaningful.
Objective Response Rate: Nearly half (47.87%) of evaluable patients in the PAAG arm achieved measurable tumor shrinkage — a rate that approaches what is typically seen only in more chemo-sensitive malignancies.
Disease Control Rate: A DCR of 92.55% indicates that the overwhelming majority of patients experienced either tumor shrinkage or disease stabilization, providing a critical window for sustained disease management.
Safety Profile: Perhaps most importantly, the addition of penpulimab and anlotinib to standard chemotherapy did not significantly increase the rate of severe adverse events. The most common grade ≥3 toxicity was leukopenia, consistent with the chemotherapy backbone. The absence of grade 5 (fatal) adverse events underscores the tolerability of this four-drug combination.

Significance in the Context of Global Pancreatic Cancer Research

The PAAG trial results should be viewed within the broader landscape of pancreatic cancer therapeutics in 2025–2026:

NAPOLI-3 (NALIRIFOX): The global phase III trial established NALIRIFOX as a new first-line option, demonstrating a median OS of 11.1 months versus 9.2 months for nab-paclitaxel/gemcitabine. The PAAG regimen’s PFS of 7.7 months compares favorably.
KRAS-targeted therapies: Novel KRAS G12D inhibitors (e.g., INCB161734, setidegrasib/ASP3082) presented at ASCO GI 2026 showed promising early-phase activity, but remain limited to the subset of patients harboring specific KRAS mutations.
Immunotherapy combinations: A meta-analysis presented at ASCO GI 2025 confirmed that immunotherapy alone has limited efficacy in pancreatic cancer. The PAAG study demonstrates that the key lies in rational combination — using antiangiogenic agents to remodel the tumor microenvironment before unleashing immune checkpoint blockade.
Daraxonrasib (RAS inhibitor): The phase III RASolute 302 trial reported positive results in 2026, representing another major advance. However, this targets a specific molecular subset, whereas PAAG offers a biomarker-unselected approach applicable to the broader patient population.

China’s Rising Contribution to Medical Oncology Innovation

The PAAG regimen exemplifies a broader trend: China’s emergence as a major contributor to innovative cancer therapeutics, particularly in medical oncology for gastrointestinal malignancies.

From Follower to Innovator

China’s oncology research ecosystem has undergone a transformation over the past decade:

Original Drug Development: Both penpulimab and anlotinib are domestically developed molecules from Chinese pharmaceutical companies, representing China’s growing capacity for novel drug discovery rather than reliance on imported therapeutics.
Innovative Combination Strategies: The PAAG regimen reflects sophisticated translational thinking — moving beyond single-agent testing to rationally designed multi-mechanism combinations informed by tumor biology.
Rigorous Clinical Trial Design: The progression from a single-arm phase II study (published in Signal Transduction and Targeted Therapy, 2024) to a randomized controlled trial demonstrates adherence to international standards of clinical evidence generation.
Global Presentation: The selection of PAAG data for presentation at ASCO GI 2026 — the premier international GI oncology meeting — reflects the growing recognition of Chinese clinical research on the world stage.

Broader Chinese Contributions to Pancreatic Cancer Treatment

The PAAG study is not an isolated achievement. Chinese researchers have made notable contributions across the pancreatic cancer treatment spectrum:

AI-powered early detection: Chinese teams have pioneered artificial intelligence approaches for early pancreatic cancer screening, addressing the critical challenge that over 80% of patients present with advanced disease.
Liquid biopsy advances: Improvements in ctDNA-based monitoring for post-surgical recurrence surveillance have emerged from Chinese institutions.
Novel immunotherapy platforms: Chinese researchers are actively developing CAR-T, CAR-NK, and CAR-macrophage approaches specifically designed to overcome the immunosuppressive pancreatic tumor microenvironment.
Neoadjuvant strategies: Chinese surgical oncology teams have contributed to optimizing perioperative treatment sequencing for borderline resectable disease.

Clinical Implications and Future Directions

For patients with newly diagnosed metastatic pancreatic cancer, the PAAG regimen offers several potential advantages:

Broad applicability: Unlike mutation-specific targeted therapies, PAAG does not require biomarker selection, making it potentially accessible to all patients with metastatic disease.
Manageable toxicity: The comparable safety profile to standard AG chemotherapy means that the addition of immunotherapy and antiangiogenic therapy does not come at the cost of significantly increased toxicity.
Extended disease control: A median PFS of 7.7 months and DCR of 92.55% translate to longer periods of disease stability, preserving quality of life and creating opportunities for subsequent lines of therapy.

Remaining Questions

Overall survival data: With median OS not yet reached at the October 2025 cutoff, mature survival data will be critical to confirm the durability of benefit.
Biomarker correlates: The biomolecular exploratory component of the study may identify subgroups that derive particular benefit from the immunotherapy and antiangiogenic components.
Phase III confirmation: A larger, multi-center randomized phase III trial will be needed to establish PAAG as a definitive new standard of care.
Global applicability: Validation in diverse patient populations outside China will be important for international adoption.

Conclusion

The PAAG regimen represents a meaningful advance in the first-line treatment of metastatic pancreatic cancer — a disease that has long resisted therapeutic innovation. By combining immune checkpoint blockade, antiangiogenic therapy, and cytotoxic chemotherapy in a biologically rational manner, Professor Du Juan’s team has demonstrated that even the most treatment-resistant cancers can be addressed through intelligent drug combination.

More broadly, the PAAG study exemplifies China’s maturation as a source of original oncology innovation. The era in which Chinese clinical research merely replicated Western trials is giving way to one in which Chinese investigators are generating novel hypotheses, developing original therapeutics, and producing practice-changing evidence that commands attention on the global stage.

As the pancreatic cancer field enters an era of unprecedented therapeutic diversity — with KRAS inhibitors, novel immunotherapy combinations, cancer vaccines, and targeted agents all advancing simultaneously — the PAAG regimen stands as a testament to what can be achieved through rigorous science, translational insight, and persistent clinical investigation.

References

Du J, et al. First-line penpulimab and anlotinib with nab-paclitaxel/gemcitabine (PAAG) in metastatic pancreatic cancer: a prospective, multicentre, biomolecular exploratory, phase II trial. Signal Transduction and Targeted Therapy. 2024. PubMed: 38844468
RCT-PAAG Study. ClinicalTrials.gov Identifier: NCT06051851
PAAG randomized data presented at 2026 ASCO Gastrointestinal Cancers Symposium, January 8–10, 2026. Targeted Oncology coverage; OncLive coverage
Research Highlights from ASCO GI 2026. Let’s Win Pancreatic Cancer
AACR Special Conference on Pancreatic Cancer 2025. AACR Program

Content was rephrased for compliance with licensing restrictions. Sources cited above.